Advertisement

A Case Study Demonstrating Superiority of a New Compound over the Gold Standard

Abstract

Some basic issues relevant for demonstration of superior efficacy are discussed with the case of the development of zoledronic acid 4 and 8 mg in hypercalcemia of malignancy. Topics such as number of studies, significance level, consistency of results across subgroups, and choice of primary efficacy variable are addressed. Two calibration studies using a comparison with a prespecified value as a criterion for efficacy are compared with one between-treatment pooled analysis. A further point is the switch from noninferiority to superiority. Some lessons for statistics can be drawn from the case study.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Warrell RP. Metabolic emergencies. In: DeVita V. Jr, Hellman S, Rosenberg SA, ed. Cancer: Principles and Practice of Oncology. Ed. 5. Philadelphia, PA: Lippincott-Raven; 1997:2486–2493.

  2. 2.

    Mundy GR. Hypercalcemia of malignancy. Am J Med 1997;103:134–145.

  3. 3.

    Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–567.

  4. 4.

    Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557–1561.

  5. 5.

    Fisher LD. One large, well-designed, multicenter study as an alternative to the usual FDA paradigm. Drug Inf J 1999;33:265–271.

  6. 6.

    Ruberg S, Cairns V. Providing evidence of efficacy for a new drug. Stat Med 1998;17:1813–1823.

  7. 7.

    Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/2330/99 Draft. Points to consider on validity and interpretation of meta-analyses, and one pivotal trial. Brussels, Belgium: Committee for Proprietary Medicinal Products; October 19, 2000.

  8. 8.

    US Department of Health and Human Services, FDA CDE. and CBER. Guidance for industry: Providing clinical evidence of effectiveness for human drug and biological products. Rockville, MD: Food and Drug Administration; May 1998.

  9. 9.

    Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/482/99 Final. Points to consider on switching between superiority and non-inferiority. Brussels, Belgium: Committee for Proprietary Medicinal Products; July 27, 2000.

  10. 10.

    Bauer P, Kieser M. A unifying approach for confidence intervals and testing of equivalence and difference. Biometrika 1996;83:934–937.

Download references

Author information

Correspondence to Erhard Quebe-Fehling PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Quebe-Fehling, E. A Case Study Demonstrating Superiority of a New Compound over the Gold Standard. Ther Innov Regul Sci 35, 1173–1178 (2001) doi:10.1177/009286150103500414

Download citation

Key Words

  • Evidence of efficacy
  • Calibration study
  • One pivotal study
  • Replication
  • Switching from noninferiority to superiority